Childhood Cancer Survivor Study/Children's Oncology Group Late Effects Assessment Protocol

NIH RePORTER · NIH · U24 · $384,642 · view on reporter.nih.gov ↗

Abstract

ABSTRACT The Childhood Cancer Survivor Study (CCSS; U24 CA055727; PI: Armstrong) is a multi-institutional, multi- disciplinary collaborative research resource established to systematically evaluate long-term outcomes among children diagnosed with cancer who survived five or more years from diagnosis. With the successful recruitment and longitudinal follow-up of the cohort that includes survivors diagnosed and treated over three decades (1970- 1999), the CCSS is the world’s largest established open resource for survivorship research with 38,036 eligible survivors available for investigation of late mortality, and 25,665 participants who have contributed health-related and quality of life outcomes. The resource includes comprehensive annotation of treatment exposures, ongoing longitudinal follow-up and an established biorepository from which genotype (single nucleotide polymorphisms [SNP] array) and DNA sequencing of 8,380 survivors are available to investigators for identification of genetic susceptibility for disease- and treatment- related late effects. The objective of the current supplement application is to pilot recruitment of participants from two Children’s Oncology Group (COG) clinical trials for treatment of Hodgkin lymphoma (HL). Results will inform a future expansion of the Childhood Cancer Survivor Study.

Key facts

NIH application ID
11075438
Project number
3U24CA055727-30S1
Recipient
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
Principal Investigator
Gregory Armstrong
Activity code
U24
Funding institute
NIH
Fiscal year
2024
Award amount
$384,642
Award type
3
Project period
2024-05-01 → 2026-11-30